Will comment more on this after Q4 and SAR are out. Looks high to me. why do you continue to us AU$ with VAT for NdPr prices when the whole world, ex China, including Lynas in all there documents and CCs uses USD NV? are you trying to confuse people? Also the 2022 AR is out and the 2023 SAR is out why not use real numbers yours are low. this does make your prediction for future look better.
2021 from 2022AR Revenue $490M $Profit 157M
2022 AR https://wcsecure.weblink.com.au/pdf/LYC/02558707.pdf Revenue AU$ 920m Net profit $540
2023 SAR https://wcsecure.weblink.com.au/pdf/LYC/02636506.pdf H1 revenue AU$370, Net profit $150M
Should you not at least use the latest publish data from Lynas?
Here is what I think your charts say, correct me if I am wrong For revenue lets use SAR + Q3+ Q4
For profits use AR
For SP use 3 weeks after AR release. Explanation SP bounces a lot for first few weeks after any major announcement, let it settle.
I used your worse case numbers so it should be easy to beat them.
- Forums
- ASX - By Stock
- LYC
- Deciphering Lynas
LYC
lynas rare earths limited
Add to My Watchlist
3.48%
!
$8.88

Deciphering Lynas, page-473
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$8.88 |
Change
-0.320(3.48%) |
Mkt cap ! $8.306B |
Open | High | Low | Value | Volume |
$9.44 | $9.44 | $8.86 | $61.13M | 6.800M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
7 | 225 | $8.88 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$8.91 | 24100 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 2 | 8.880 |
1 | 80 | 8.850 |
1 | 508 | 8.830 |
1 | 675 | 8.820 |
6 | 3145 | 8.800 |
Price($) | Vol. | No. |
---|---|---|
8.930 | 200 | 1 |
8.950 | 200 | 1 |
8.960 | 650 | 1 |
8.990 | 164 | 1 |
9.020 | 1100 | 1 |
Last trade - 16.11pm 27/06/2025 (20 minute delay) ? |
Featured News
LYC (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online